HRS 25 - First-in-human data from the FIH VCAS trial suggests the FieldForce Ablation system can effectively create transmural ablation lesions in patients with scar-related ventricular tachycardia (VT), with an 80% freedom from VT and ventricular fibrillation rate at 6 months.

We are joined by Dr Vivek Reddy (Mount Sinai Hospital, New York, US) to discuss the findings from the prospective, first-in-human, single-arm VCAS trial (NCT06203262) investigating the safety and feasibility of the FieldForce Ablation system in patients with scar-related VT.

Interview Questions:
1. What is the importance of this study?
2. Would you tell us about the FieldForce Ablation System?
3. What was the study design and patient population?
4. What were your key findings?

Recorded remotely from New York, 2025.

Editors: Jordan Rance, Yazmin Sadik
Videographers: David Ben-Harosh

Support: This is an independent interview produced by Arrhythmia Academy.